Nadroparin calcium
Highest phase reached
Approved
Drug type
Oligosaccharide
First approval year
2018
- First approval year
- 2018
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Oligosaccharide
- Drug name
- Nadroparin calcium
- cy 216
- CY 216
- CY-216
- fraxiparin
- Fraxiparin
- fraxiparina
- Fraxiparina
- fraxiparine
- Fraxiparine
- nadroparin
- Nadroparin
- Nadroparin (intravenous Infusion)
- Nadroparin (subcutaneous group)
- nadroparin calcium
- Nadroparin calcium
- Nadroparin Calcium
- NADROPARIN CALCIUM [EP MONOGRAPH]
- nadroparin calcium [INN]
- Nadroparin calcium [WHO-DD]
- nadroparin calcium ep monograph
- nadroparin calcium inn
- nadroparin calcium who dd
- nadroparin calcium-warfarin sequential anticoagulation
- nadroparina calcica
- Nadroparina calcica
And 6 more, listed on the interactive page.
- ATC classification codes
- B01AB06
Sources for recorded values
- CAS registry numbers
- 37270-89-6
- ChEMBL ID
- CHEMBL2109204
- FDA ingredient codes (UNII)
- LIA7Z4002P
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -parin
Mechanisms of action
- Mechanism
- Antithrombin-III activator
- Action type
- ACTIVATOR
- Target
- Antithrombin-III
- Protein identifier
- P01008
Open Targets mechanisms
- Mechanism
- Antithrombin-III activator
- Action type
- ACTIVATOR
- Target
- Antithrombin-III
- Condition
- Venous Thrombosis
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003907
- Subject identifier
- D020246
- Condition
- Venous Thromboembolism
- Highest recorded phase
- 3
- Condition identifier
- EFO:0004286
- Subject identifier
- D054556
- Condition
- Thrombophilia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0009315
- Subject identifier
- D019851
- Condition
- Thrombosis
- Highest recorded phase
- 3
- Condition identifier
- HP:0004419
- Subject identifier
- D013927
- Condition
- Venous Thrombosis
- Highest recorded phase
- 3
- Condition identifier
- HP:0004936
- Subject identifier
- D020246
- Condition
- Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0004992
- Subject identifier
- D009369
- Condition
- Lung Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0008903
- Subject identifier
- D008175
- Condition identifier
- EFO_0003907
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004286
- Highest recorded phase
- 3
- Condition identifier
- EFO_0004352
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009314
- Condition identifier
- EFO_0009315
- Highest recorded phase
- 3
- Condition identifier
- HP_0001297
- Condition identifier
- HP_0001907
- Highest recorded phase
- 3
- Condition identifier
- HP_0004419
- Condition identifier
- HP_0004419
- Highest recorded phase
- 4
- Condition identifier
- HP_0004936
- Highest recorded phase
- 3
- Condition identifier
- HP_0005268
- Highest recorded phase
- 3
- Condition identifier
- HP_0030242
- Condition identifier
- MONDO_0000491
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0000831
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0001531
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004992
- Condition identifier
- MONDO_0004992
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005030
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005081
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005099
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005155
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005279
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005298
- Condition identifier
- MONDO_0005399
- Highest recorded phase
- 3
And 6 more, listed on the interactive page.
- Event
- abdominal wall haematoma
- Reports
- 47
- Reporting signal score
- 126.72
- Event
- activated partial thromboplastin time prolonged
- Reports
- 155
- Reporting signal score
- 436.864
- Event
- anaemia of chronic disease
- Reports
- 5
- Reporting signal score
- 21.0776
- Event
- arthralgia
- Reports
- 15
- Reporting signal score
- 92.6074
- Event
- autoimmune disorder
- Reports
- 7
- Reporting signal score
- 20.8311
- Event
- bronchopulmonary dysplasia
- Reports
- 6
- Reporting signal score
- 26.3895
- Event
- cardiac tamponade
- Reports
- 67
- Reporting signal score
- 151.386
- Event
- cerebral haemorrhage
- Reports
- 118
- Reporting signal score
- 171.537
- Event
- coagulation time shortened
- Reports
- 27
- Reporting signal score
- 102.138
- Event
- deep vein thrombosis
- Reports
- 264
- Reporting signal score
- 287.934
- Event
- diarrhoea
- Reports
- 42
- Reporting signal score
- 132.587
- Event
- erysipelas
- Reports
- 8
- Reporting signal score
- 23.4447
- Event
- extradural haematoma
- Reports
- 34
- Reporting signal score
- 88.0996
- Event
- fatigue
- Reports
- 33
- Reporting signal score
- 165.038
- Event
- fistula
- Reports
- 8
- Reporting signal score
- 19.735
- Event
- foetal growth restriction
- Reports
- 63
- Reporting signal score
- 118.83
- Event
- gastrointestinal haemorrhage
- Reports
- 196
- Reporting signal score
- 152.541
- Event
- haematocrit decreased
- Reports
- 120
- Reporting signal score
- 173.06
- Event
- haematoma
- Reports
- 234
- Reporting signal score
- 432.754
- Event
- haemoglobin decreased
- Reports
- 270
- Reporting signal score
- 212.58
- Event
- haemorrhage
- Reports
- 333
- Reporting signal score
- 435.878
- Event
- haemorrhage intracranial
- Reports
- 104
- Reporting signal score
- 183.189
- Event
- heparin-induced thrombocytopenia
- Reports
- 1,171
- Reporting signal score
- 5,849.9
- Event
- heparin-induced thrombocytopenia test
- Reports
- 24
- Reporting signal score
- 119.943
- Event
- heparin-induced thrombocytopenia test positive
- Reports
- 25
- Reporting signal score
- 121.222
And 33 more, listed on the interactive page.
- NCT00312013
- NCT00843492
- NCT00421538
- NCT00951574
- NCT01019655
- NCT01431456
- NCT04066764
- NCT01980849
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (516)
- "Postoperative Pain Following Laser-Assisted Root Canal Treatment: A Randomized Clinical Trial"
- (RIGHT HEART III Study - Right Ventricular Hemodynamic Evaluation and Response to Treatment)
- 6MW3511 in Patients With Advanced Solid Tumor
- A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
- A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
- A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors
- A Clinical Study of YL205 in Patients With Advanced Solid Tumors
- A Clinical Study on Co-transplantation of Autologous Limbal Stem Cells and Corneal Stromal Stem Cells to Repair Corneal Injury
- A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy
- A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
- A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A Dose-ranging Trial of OPC-131461 in Cardiac Edema (Congestive Heart Failure [CHF])
- A Dose-response Study of Tranexamic Acid in Total Hip Arthroplasty
- A Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Evaluate the Safety and Efficacy of DT2-SCT in Subjects With Type 2 Diabetes Mellitus
- A Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy
- A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients
- A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
- A Phase 1 Study to Evaluate the Safety, Reactogenicity and Immunogenicity of YKYY025 Injection
- A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight
In development for (5)
- Cancer Phase 3
- Lung cancer Phase 3
- Thrombophilia Phase 3
- Thrombotic disease Phase 3
- Venous thromboembolism Phase 3
Other linked conditions (1)
- Blood coagulation disease
Targets (1)
- SERPINC1 Antithrombin-III activator